Minimal effects of JL 13, a pyridobenzoxazepine derivative with an antipsychotic potential, on circulating prolactin levels in male rats

被引:5
作者
Liégeois, JF
Bruhwyler, J
Hendrick, JC
Delarge, J
Legros, JJ
Damas, J
机构
[1] Univ Liege, Med Chem Lab, B-4000 Liege 1, Belgium
[2] Univ Liege, Physiol Lab, B-4020 Liege, Belgium
[3] Univ Liege, Endocrine Serv, Lab Neuroendocrinol & Radioimmunol, B-4000 Liege 1, Belgium
关键词
antipsychotic; clozapine; antagonist; D-2; receptors; haloperidol; serotonin; prolactin; rats;
D O I
10.1016/S0304-3940(01)02539-3
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Antipsychotic therapy is frequently associated with several side effects such as hyperprolactinemia. The influence of a putative antipsychotic JL 13 on prolactin release was assessed after intraperitoneal injection in gentled male rats in comparison with clozapine and haloperidol. A total of 30 or 150 min after administration, whole blood was collected for preparing serum samples. Prolactin was quantified by radioimmunoassay method. At 30 min, JL 13 like clozapine, increased prolactin concentration only at the higher dose (30 mg/kg) while haloperidol at both tested doses induced a dramatic increase of prolactin concentration. At 150 min after injection, only haloperidol (0.3 mg/kg) significantly increased serum prolactin level. This minimal effect on prolactinemia reinforces the similarity of clozapine and JL 13 regarding the atypical antipsychotic profile. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:49 / 52
页数:4
相关论文
共 20 条
[1]   Olanzapine - An updated review of its use in the management of schizophrenia [J].
Bhana, N ;
Foster, RH ;
Olney, R ;
Plosker, GL .
DRUGS, 2001, 61 (01) :111-161
[2]  
BOWDEN CR, 1992, J PHARMACOL EXP THER, V262, P699
[3]   JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: A review of its behavioural properties [J].
Bruhwyler, J ;
Liegeois, JF ;
Bergman, J ;
Carey, G ;
Goudie, A ;
Taylor, A ;
Meltzer, H ;
Delarge, J ;
Geczy, J .
PHARMACOLOGICAL RESEARCH, 1997, 36 (04) :255-264
[4]   The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates [J].
Casey, DE ;
Bruhwyler, J ;
Delarge, J ;
Géczy, J ;
Liégeois, JF .
PSYCHOPHARMACOLOGY, 2001, 157 (03) :228-235
[5]   ANTIPSYCHOTIC-DRUGS STIMULATE PROLACTIN-RELEASE [J].
CLEMENS, JA ;
SMALSTIG, EB ;
SAWYER, BD .
PSYCHOPHARMACOLOGIA, 1974, 40 (02) :123-127
[6]  
Ellenbroek BA, 2001, J PHARMACOL EXP THER, V298, P386
[7]   EVIDENCE THAT THE MEDIAL AND DORSAL RAPHE NUCLEI MEDIATE SEROTONERGICALLY-INDUCED INCREASES IN PROLACTIN-RELEASE FROM THE PITUITARY [J].
FESSLER, RG ;
DEYO, SN ;
MELTZER, HY ;
MILLER, RJ .
BRAIN RESEARCH, 1984, 299 (02) :231-237
[8]   DIFFERENTIAL-EFFECTS OF HALOPERIDOL, CLOZAPINE, AND FLUPERLAPINE ON TUBEROINFUNDIBULAR DOPAMINE NEURONS AND PROLACTIN SECRETION IN THE RAT [J].
GUDELSKY, GA ;
KOENIG, JI ;
SIMONOVIC, M ;
KOYAMA, T ;
OHMORI, T ;
MELTZER, HY .
JOURNAL OF NEURAL TRANSMISSION, 1987, 68 (3-4) :227-240
[9]   Distribution of the methylpiperazinopyridobenzoxazepine derivative JL13, a potential antipsychotic, in rat brain [J].
Guiso, G ;
Caccia, S .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2001, 53 (03) :317-321
[10]   PHARMACOKINETICS OF THE NOVEL ANTIPSYCHOTIC AGENT RISPERIDONE AND THE PROLACTIN RESPONSE IN HEALTHY-SUBJECTS [J].
HUANG, ML ;
VANPEER, A ;
WOESTENBORGHS, R ;
DECOSTER, R ;
HEYKANTS, J ;
JANSEN, AAI ;
ZYLICZ, Z ;
VISSCHER, HW ;
JONKMAN, JHG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (03) :257-268